Skip to content
Clinical Trials – home
SwedenBack to Sweden

Clinical trials in Landskrona – page 103

1 405 clinical trials in Landskrona, Sweden. Every trial is listed in the EU Clinical Trials Register and updated daily.

SwedenOur site in SwedenKliniska-Provningar.se(opens in a new tab)
Landskrona at a glance
1 405
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

1 405 trials in Landskrona

Open in trial search

Study on Obinutuzumab, Chlorambucil, and Acalabrutinib for Patients with Untreated Chronic Lymphocytic Leukemia

Registered drugNo placebo
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:Acalabrutinib
  • Sponsor:Acerta Pharma B.V.

Neoplasm

Not recruiting

Study on the Effectiveness of Inavolisib, Atezolizumab, and Entrectinib in Patients with Advanced or Metastatic Solid Tumors

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Alectinib
  • Sponsor:F. Hoffmann-La Roche AG

Study on Dostarlimab, Carboplatin, and Paclitaxel for Patients with Recurrent or Advanced Endometrial Cancer

Registered drug
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:Dostarlimab
  • Sponsor:Tesaro Inc.

Study on Golcadomide and R-CHOP Drug Combination for Patients with Untreated High-risk Large B-cell Lymphoma

Registered drug
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:Apixaban
  • Sponsor:Celgene Corp.

Study Comparing Teclistamab with Daratumumab, Pomalidomide, and Dexamethasone for Patients with Relapsed or Refractory Multiple Myeloma

Registered drugNo placebo
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:Bortezomib
  • Sponsor:Janssen Cilag International

Study on Deucrictibant and Icatibant for Treating Hereditary Angioedema Attacks in Adolescents and Adults

Registered drug
Countries:SwedenSweden
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Deucrictibant
  • Sponsor:Pharvaris Netherlands B.V.

Study of Lecanemab (BAN2401) Treatment in People with Early Alzheimer's Disease: Testing Safety and Effectiveness Over 18 Months

InvestigationalNo placebo
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:Lecanemab
  • Sponsor:Eisai Limited

Open angle glaucoma

Not recruiting

Study on the Effectiveness of Bimatoprost SR for Patients with Open-Angle Glaucoma or Ocular Hypertension

InvestigationalNo placebo
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:Bimatoprost
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Study Comparing Ibrutinib, Venetoclax, and Obinutuzumab for Untreated Chronic Lymphocytic Leukemia Patients

Registered drugNo placebo
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:Ibrutinib
  • Sponsor:University Of Cologne

Atrial fibrillation+2

Not recruiting

Study on Asundexian and Apixaban for Preventing Stroke in Adults with Atrial Fibrillation at Risk for Stroke

Registered drug
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:Apixaban
  • Sponsor:Bayer AG

Plasma cell myeloma

Not recruiting

Study on Human Normal Immunoglobulin to Prevent Early Infections in Patients with Newly Diagnosed Multiple Myeloma Not Eligible for Transplant

Registered drugNo placebo
Countries:DenmarkDenmark
  • Participants:18–64 years · 65+ years
  • Substances:Human Normal Immunoglobulin
  • Sponsor:Lillebaelt Hospital

Malignant melanoma

Not recruiting

Study of mRNA-4157 and Pembrolizumab for Patients with High-Risk Stage II-IV Melanoma

Registered drug
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:MRNA-4157
  • Sponsor:Merck Sharp & Dohme LLC

Other cities in Sweden

The busiest research cities in the country

All 66 cities in Sweden

Clinical research in Landskrona

What the registry says about research in the country

01 Cardiovascular Research

Innovative clinical research focusing on heart failure with preserved ejection fraction (HFpEF), evaluating the effectiveness of spironolactone and eplerenone treatments combined with standard care approaches.

  • Heart Failure Management
  • Cardiovascular Outcomes
  • Treatment Optimization

The research aims to reduce hospitalization rates and improve cardiovascular survival outcomes through registry-based methodologies.

02 Urological Oncology

Groundbreaking research in non-muscle invasive bladder cancer treatment, comparing the efficacy of adjuvant therapies using gemcitabine versus mitomycin in intermediate-risk cases.

  • Bladder Cancer Treatment
  • Recurrence Prevention
  • Post-surgical Care

This study focuses on improving recurrence-free survival rates following transurethral tumor resection procedures.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.